UroGen Pharma (URGN) Debt to Equity (2022 - 2025)
Historic Debt to Equity for UroGen Pharma (URGN) over the last 4 years, with Q3 2025 value amounting to -$1.06.
- UroGen Pharma's Debt to Equity fell 12218.15% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.06, marking a year-over-year decrease of 12218.15%. This contributed to the annual value of -$13.83 for FY2024, which is 81505.6% down from last year.
- As of Q3 2025, UroGen Pharma's Debt to Equity stood at -$1.06, which was down 12218.15% from -$1.31 recorded in Q2 2025.
- In the past 5 years, UroGen Pharma's Debt to Equity registered a high of $4.77 during Q3 2024, and its lowest value of -$13.83 during Q4 2024.
- Over the past 4 years, UroGen Pharma's median Debt to Equity value was -$1.31 (recorded in 2025), while the average stood at -$1.79.
- The largest annual percentage gain for UroGen Pharma's Debt to Equity in the last 5 years was 55442.29% (2024), contrasted with its biggest fall of 81505.6% (2024).
- Quarter analysis of 4 years shows UroGen Pharma's Debt to Equity stood at -$1.09 in 2022, then crashed by 38.46% to -$1.51 in 2023, then plummeted by 815.06% to -$13.83 in 2024, then surged by 92.35% to -$1.06 in 2025.
- Its Debt to Equity stands at -$1.06 for Q3 2025, versus -$1.31 for Q2 2025 and -$2.63 for Q1 2025.